Evidence supporting a theory that proteins linked to neurological diseases such as Alzheimer’s can be transferred from sick to healthy patients continues to accumulate. Speaking of Alzheimer’s, Eli Lilly signed a deal with AC Immune to develop a treatment. In other news, Biogen backed down from a US$1 billion deal to develop a treatment for rare eye diseases.
In Mexico, President Andrés Manuel López Obrador announced the country’s transition to a new healthcare model, Farmacias Guadalajara’s operator said it would build a third distributor center, Stendhal Pharma won a tender to sell HIV antiretrovirals to IMSS, INEGI indicated that the healthcare sector represented MX$1.2 billion in 2017 and a Canadian company signed a deal to become the first distributor of cannabis products in the country.
Global Health Intelligence’s Guillaume Copart spoke to Mexico Health Review on the way Big Data can support healthcare operations.
Now, jump into last week’s highlights:
President López Obrador announced a new healthcare system in which all services will be provided by the federal government within the next two years. The president also announced that Seguro Popular will be replaced by a new model.
INEGI stated that the healthcare sector’s added value represented 5.6 percent of Mexico’s GDP in 2017, a total of This value represents all economic activities directly or indirectly related to prevention, care and management of health.
Canadian Aurora Cannabis to buy Farmacias Magistrales. This will allow the Canadian company to import medical supplies containing tetrahydrocannabinol.
The operator of Farmacias Guadalajara will invest MX$1.6 billion in the construction of a third distribution center in Hidalgo, Mexico.
Stendhal Pharma won a tender to sell HIV antiretrovirals to IMSS for a value of approximately MX$662 million.
Biogen backed down from a US$1 billion deal with AGTC to develop a gene therapy for treating rare eye diseases, sending the latter’s shares plunging.
Eli Lilly signed a US$81 million deal with AC Immune to develop the latter’s tau aggregation inhibitors. These products are meant to reduce tau aggregates and improve the memory of Alzheimer’s patients.
Scientists point to growing evidence that the proteins characteristic of Alzheimer’s and other neurodegenerative diseases can be transferred between patients and may lead to brain disease years later.